Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care

  title={Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care},
  author={Melissa J. Nirenberg},
  journal={Drugs \& Aging},
Dopamine agonists are effective treatments for a variety of indications, including Parkinson’s disease and restless legs syndrome, but may have serious side effects, such as orthostatic hypotension, hallucinations, and impulse control disorders (including pathological gambling, compulsive eating, compulsive shopping/buying, and hypersexuality). The most effective way to alleviate these side effects is to taper or discontinue dopamine agonist therapy. A subset of patients who taper a dopamine… 
Management of impulse control disorders in Parkinson's disease
Cognitive behavioral therapy has been shown to improve ICD symptoms in the only published study, although further research is urgently needed.
A Man With Persistent Dopamine Agonist Withdrawal Syndrome After 7 Years Being Off Dopamine Agonists
The case of a 64-year-old right-handed man who experienced impulse-control disorder (ICD) while being treated with dopamine agonists, developed DAWS upon discontinuation of dopamine agonism, and remained off dopamine agonist for 7 years, despite presenting symptoms that significantly impaired his quality of life.
An Update on Medical and Surgical Treatments of Parkinson’s Disease
The diagnosis of PD is mainly clinical, but dopamine transporter single-photon emission computed tomography can improve the accuracy of the diagnosis, and dopamine based therapies are used for the treatment of motor symptoms.
A Case Report of Severe Delirium after Amantadine Withdrawal
The case of a 71-year-old PD patient without previously known cognitive impairment, who presented with drug-induced psychotic symptoms due to changes in his therapeutic regimen, is reported, the first report of a cognitively unimpaired patient developing an amantadine withdrawal syndrome.
Symptoms of Medication Withdrawal in Parkinson's Disease: Considerations for Informed Consent in Patient-Oriented Research.
Improve the informed consent process by identifying patient-reported symptoms when dopamine treatment is withheld and providing clinical guidance regarding the extent of these symptoms and consider participant willingness to undergo these assessments.
Impulsive compulsive behaviours in Parkinson's disease : an observational, eye movement and neuropathological study
Lower levels of alpha-synuclein were found in the nucleus accumbens of patients with ICBs suggesting a central role for this structure in the pathophysiology of ICBs.
A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease
Preliminary data indicate a high rate after discontinuation of a range of DAs, particularly in the context of impulse control disorders, as reported in this first prospective evaluation of DAWS in the clinic.
Management of impulse control disorders in Parkinson's disease: Controversies and future approaches
Controversy is focused on, including the role of more recently available anti‐parkinsonian drugs, and potential future approaches involving routes of drug delivery, nonpharmacological treatments, and other as yet experimental strategies.
Medical device alternatives to restless legs syndrome (RLS) Dopaminergic Drugs
Like the appearance of articles describing tartive dyskinesia following widespread use of anti–psychotic drugs in 1970s, reports began surfacing of worrisome mid– and longer–term complication following dopaminergic drug treatment of RLS.


Dopamine agonist withdrawal syndrome in Parkinson disease.
Dopamine agonists have a stereotyped withdrawal syndrome that can lead to profound disability in a subset of patients and Physicians should monitor patients closely when tapering these medications.
Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome.
Clinical Review and Treatment of Select Adverse Effects of Dopamine Receptor Agonists in Parkinson’s Disease
Dopamine receptor agonists provide a viable alternative or adjunct to levodopa therapy in Parkinson’s disease and are associated with fewer motor complications and dyskinesia. However, all available
Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson's disease surgery.
My strong suspicion, however, is that severe non-motor symptoms that occur after deep brain stimulation are largely attributable to dopamine agonist withdrawal syndrome (DAWS) rather than a non-specific dopamine withdrawal state.
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic
Critical features of the syndrome are the strong link with impulse control disorders, possibly the independence of DA dosage and type, and the resistance to treatment, including levodopa.
Compulsive eating and weight gain related to dopamine agonist use
  • M. J. NirenbergC. Waters
  • Psychology, Medicine
    Movement disorders : official journal of the Movement Disorder Society
  • 2006
Physicians should be aware that compulsive eating resulting in significant weight gain may occur in PD as a side‐effect of dopamine agonist medications such as pramipexole.
Reply: Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson’s disease surgery
This study identified preoperative non-motor fluctuations as predictors of post-operative apathy and demonstrated that non-Motor psychic symptoms of Parkinson’s disease can be explained by mesolimbic dopaminergic denervation.
Impulse Control Disorders Associated With Dopaminergic Medication in Patients With Pituitary Adenomas
This study demonstrates the importance of systematic screening for ICDs in patients taking dopaminergic medication regardless of their primary condition, and indicates the need for systematic screening in patients with pituitary adenomas who take dopamine agonists.
Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome
RLS patients treated with dopaminergic agents and dopamine agonists in particular, should be forewarned of potential side effects and a careful history of risk factors should be taken.
Addiction-Like Manifestations and Parkinson's Disease: A Large Single Center 9-Year Experience
Dopaminergic therapy in a subset of PD patients was strongly associated with addiction-like behavioral issues and there was a strong relationship between DAWS, DDS, and ICD in this large PD cohort.